Abstract 230P
Background
SOLO1 (NCT01844986) is a randomized, double-blind, phase III trial evaluating the efficacy and safety of the PARP inhibitor, olaparib, as maintenance monotherapy in newly diagnosed advanced OC pts with a BRCAm. A separate pt cohort evaluated the efficacy and safety of olaparib in Chinese pts in this setting.
Methods
The China cohort of SOLO1 planned to enrol ∼53 newly diagnosed OC pts who had completed first-line platinum-based chemotherapy and were in clinical complete or partial response. This sample size provided around a 90% chance to observe a hazard ratio (HR) of < 1, assuming a true HR of 0.62. Pts were randomized 2:1 to olaparib (300 mg bid; tablet) vs placebo. The primary endpoint was investigator-assessed progression-free survival (PFS; modified RECIST v1.1). Sensitivity analysis of PFS was performed by blinded independent central review (BICR).
Results
All 64 randomized pts received study treatment (olaparib, n = 44; placebo n = 20). Median follow-up was ∼30 months in both arms. Median PFS was not reached in the olaparib arm and was 9.3 months in the placebo arm (Table).
Table: 230P
PFS events, n | Median PFS, months | HR (95% CI; P value) | |||
---|---|---|---|---|---|
Olaparib (n = 44) | Placebo (n = 20) | Olaparib (n = 44) | Placebo (n = 20) | Full analysis set (n = 64) | |
PFS, investigator assessed (48.4% maturity) | 18 | 13 | NR | 9.3 | 0.46 (0.23, 0.97; 0.0320) |
PFS, BICR (39.1% maturity) | 13 | 12 | NR | 9.3 | 0.39 (0.17, 0.86; 0.0168) |
CI, confidence interval; NR, not reached.
The most common AEs in the olaparib group were nausea (n = 28, 63.6%), anaemia (n = 25, 56.8%) and vomiting (n = 18, 40.9%). Grade ≥3 AEs occurred in 56.8% of olaparib pts vs 30.0% of placebo pts; the most common grade ≥3 AE was anaemia (n = 16, 36.4%). Olaparib dose interruptions, reductions and discontinuations occurred in 56.8%, 27.3% and 6.8% of pts, respectively (vs 30.0%, 10% and 0% of pts in the placebo arm).
Conclusions
In the China cohort of SOLO1, a clinically relevant improvement in investigator-assessed PFS was observed in newly diagnosed OC pts receiving olaparib maintenance therapy. Olaparib treatment led to a 54% reduction in risk of progression or death vs placebo. The safety results were consistent with the known profile of olaparib in Chinese pts.
Clinical trial identification
NCT01844986, release date 19 February 2016.
Editorial acknowledgement
Medical writing assistance was provided by Laura Smart, MChem, from Mudskipper Business Ltd, funded by AstraZeneca and Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA (MSD).
Legal entity responsible for the study
AstraZeneca.
Funding
AstraZeneca.
Disclosure
J. Liu: Research grant / Funding (institution): AstraZeneca. X. Ma: Full / Part-time employment: AstraZeneca. J. Zhang: Shareholder / Stockholder / Stock options, Full / Part-time employment: AstraZeneca. All other authors have declared no conflicts of interest.
Resources from the same session
340TiP - A multicenter, randomized, controlled, phase II trial exploring adjuvant combined therapy of apatinib and SHR-1210 (anti-PD-1), in patients with hepatocellular carcinoma at high risk of recurrence after radical resection
Presenter: Shida Yan
Session: Poster display session
Resources:
Abstract
347P - Relationship between modified surgical margin and prognosis of cutaneous squamous cell carcinoma
Presenter: Yukiko Teramoto
Session: Poster display session
Resources:
Abstract
348P - Malignant melanoma: A study of clinical profiles and treatment outcomes in Indian patients
Presenter: Sorun Shishak
Session: Poster display session
Resources:
Abstract
349P - Flavonoids from ethanol extracts of euphorbia hirta inhibit melanoma growth and metastatic potential
Presenter: Shubhra Mishra
Session: Poster display session
Resources:
Abstract
350P - Low-dose cisplatin and 5-fluorouracil combined concurrent chemoradiotherapy for unresectable cutaneous squamous cell carcinoma: Analysis of 23 cases
Presenter: Azusa Hiura
Session: Poster display session
Resources:
Abstract
353P - A prediction model for the intents regarding life-sustaining treatment decisions in patients with terminal cancer
Presenter: Yoonsun Kim
Session: Poster display session
Resources:
Abstract
354P - Predictive factors and survival outcomes with stereotactic body radiation therapy in treatment of oligometastases in colorectal cancer
Presenter: Vibhay Pareek
Session: Poster display session
Resources:
Abstract
355P - Cost analysis and overview of single versus multiple fraction palliative radiotherapy for painful bone metastasis
Presenter: Vinodhkumar Selvaraj
Session: Poster display session
Resources:
Abstract
356P - Observational study on role of crude cannabis in pain control and quality of life in terminally ill cancer patients: An Indian perspective
Presenter: Vidyasagar Dusi
Session: Poster display session
Resources:
Abstract
357P - Application of multi-modal approach to palliation in end of life head and neck cancer pain
Presenter: Srujana Joga
Session: Poster display session
Resources:
Abstract